MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. today announced that the company has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the ...

Sexual and endocrinologic abnormalities were rarely reported in patients with generalized epilepsies compared to limbic epilepsies. We hypothesize that men with generalized epilepsy have high ...

The FDA also approved Vimpat Injection for use in pediatric patients 4 years of age and older. The Food and Drug Administration (FDA) has approved Vimpat ® (lacosamide; UCB) as adjunctive therapy in ...

-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...

Please provide your email address to receive an email when new articles are posted on . Among 2,214 persons with epilepsy, 7.5% had MDD, and 4% had generalized anxiety disorder. Those on valproic acid ...

New Brunswick, N.J. (October 28, 2021) – Combining electroencephalogram (EEG) data with clinical observations can help doctors to better determine whether generalized epilepsy patients will respond to ...

In this interview, News-Medical talks to Dr. Gary Heiman and Dr. Brad Kamitaki about their research in devising a new diagnostic model to predict how generalized epilepsy patients will respond to drug ...

Experts emphasized the crucial role of raising awareness about the availability of advanced treatment. A collective effort can strengthen the fight against a serious population health problem. On ...

A series of conceptual reconsiderations and therapeutic advances in recent years has resulted in meaningful changes in the classification, diagnosis, and treatment of epilepsy. The first step in ...

Researchers aimed to identify the characteristics, treatment pathways, and outcomes associated with epilepsy with eyelid myoclonia (EEM). Epilepsy with eyelid myoclonia (EEM) is a rare and ...